Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Circulating Glioma Cells Exhibit Stem Cell-like Properties.

Liu T, Xu H, Huang M, Ma W, Saxena D, Lustig RA, Alonso-Basanta M, Zhang Z, O'Rourke DM, Zhang L, Gong Y, Kao GD, Dorsey JF, Fan Y.

Cancer Res. 2018 Dec 1;78(23):6632-6642. doi: 10.1158/0008-5472.CAN-18-0650. Epub 2018 Oct 15.

PMID:
30322863
2.

Circulating Tumor Cell Assessment in Presumed Early Stage Non-Small Cell Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy: A Prospective Pilot Study.

Frick MA, Kao GD, Aguarin L, Chinniah C, Swisher-McClure S, Berman AT, Levin WP, Cengel KA, DeCesaris C, Hahn SM, Dorsey JF, Simone CB 2nd.

Int J Radiat Oncol Biol Phys. 2018 Nov 1;102(3):536-542. doi: 10.1016/j.ijrobp.2018.06.041. Epub 2018 Jul 2.

PMID:
30244877
3.

Temporal DNA-PK activation drives genomic instability and therapy resistance in glioma stem cells.

Wang Y, Xu H, Liu T, Huang M, Butter PP, Li C, Zhang L, Kao GD, Gong Y, Maity A, Koumenis C, Fan Y.

JCI Insight. 2018 Feb 8;3(3). pii: 98096. doi: 10.1172/jci.insight.98096. [Epub ahead of print]

4.

Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma.

Xu MJ, Dorsey JF, Amaravadi R, Karakousis G, Simone CB 2nd, Xu X, Xu W, Carpenter EL, Schuchter L, Kao GD.

Oncologist. 2016 Jan;21(1):84-94. doi: 10.1634/theoncologist.2015-0207. Epub 2015 Nov 27. Review.

5.

A novel approach for the detection and genetic analysis of live melanoma circulating tumor cells.

Xu MJ, Cooke M, Steinmetz D, Karakousis G, Saxena D, Bartlett E, Xu X, Hahn SM, Dorsey JF, Kao GD.

PLoS One. 2015 Mar 25;10(3):e0123376. doi: 10.1371/journal.pone.0123376. eCollection 2015.

6.

Tracking viable circulating tumor cells (CTCs) in the peripheral blood of non-small cell lung cancer (NSCLC) patients undergoing definitive radiation therapy: pilot study results.

Dorsey JF, Kao GD, MacArthur KM, Ju M, Steinmetz D, Wileyto EP, Simone CB 2nd, Hahn SM.

Cancer. 2015 Jan 1;121(1):139-49. doi: 10.1002/cncr.28975. Epub 2014 Sep 19.

7.

Application of a telomerase-based circulating tumor cell (CTC) assay in bladder cancer patients receiving postoperative radiation therapy: a case study.

Ju M, Kao GD, Steinmetz D, Chandrasekaran S, Keefe SM, Guzzo TJ, Christodouleas JP, Hahn SM, Dorsey JF.

Cancer Biol Ther. 2014 Jun 1;15(6):683-7. doi: 10.4161/cbt.28412. Epub 2014 Mar 11.

8.

Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay.

Macarthur KM, Kao GD, Chandrasekaran S, Alonso-Basanta M, Chapman C, Lustig RA, Wileyto EP, Hahn SM, Dorsey JF.

Cancer Res. 2014 Apr 15;74(8):2152-9. doi: 10.1158/0008-5472.CAN-13-0813. Epub 2014 Feb 13.

9.

Theranostic gold nanoparticles modified for durable systemic circulation effectively and safely enhance the radiation therapy of human sarcoma cells and tumors.

Joh DY, Kao GD, Murty S, Stangl M, Sun L, Al Zaki A, Xu X, Hahn SM, Tsourkas A, Dorsey JF.

Transl Oncol. 2013 Dec 1;6(6):722-31. eCollection 2013 Dec 1.

10.

Gold nanoparticles in radiation research: potential applications for imaging and radiosensitization.

Dorsey JF, Sun L, Joh DY, Witztum A, Kao GD, Alonso-Basanta M, Avery S, Hahn SM, Al Zaki A, Tsourkas A.

Transl Cancer Res. 2013 Aug 1;2(4):280-291.

11.

Selective targeting of brain tumors with gold nanoparticle-induced radiosensitization.

Joh DY, Sun L, Stangl M, Al Zaki A, Murty S, Santoiemma PP, Davis JJ, Baumann BC, Alonso-Basanta M, Bhang D, Kao GD, Tsourkas A, Dorsey JF.

PLoS One. 2013 Apr 30;8(4):e62425. doi: 10.1371/journal.pone.0062425. Print 2013.

12.

Enhancing the efficacy of drug-loaded nanocarriers against brain tumors by targeted radiation therapy.

Baumann BC, Kao GD, Mahmud A, Harada T, Swift J, Chapman C, Xu X, Discher DE, Dorsey JF.

Oncotarget. 2013 Jan;4(1):64-79.

13.

Stereotactic intracranial implantation and in vivo bioluminescent imaging of tumor xenografts in a mouse model system of glioblastoma multiforme.

Baumann BC, Dorsey JF, Benci JL, Joh DY, Kao GD.

J Vis Exp. 2012 Sep 25;(67). pii: 4089. doi: 10.3791/4089.

14.

An integrated method for reproducible and accurate image-guided stereotactic cranial irradiation of brain tumors using the small animal radiation research platform.

Baumann BC, Benci JL, Santoiemma PP, Chandrasekaran S, Hollander AB, Kao GD, Dorsey JF.

Transl Oncol. 2012 Aug;5(4):230-7. Epub 2012 Aug 1.

15.

A 10-year analysis of American Society For Radiation Oncology Junior Faculty Career Development Awards.

Kimple RJ, Kao GD; Research Evaluation Committee of the ASTRO Research Council.

Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):924-8. doi: 10.1016/j.ijrobp.2012.07.2361. Epub 2012 Aug 25.

PMID:
22929862
16.

A role for the histone deacetylase HDAC4 in the life-cycle of HIV-1-based vectors.

Smith JA, Yeung J, Kao GD, Daniel R.

Virol J. 2010 Sep 16;7:237. doi: 10.1186/1743-422X-7-237.

17.

Lack of compliance with national vaccination guidelines in oncology patients receiving radiation therapy.

Yee SS, Dutta PR, Solin LJ, Vapiwala N, Kao GD.

J Support Oncol. 2010 Jan-Feb;8(1):28-34.

PMID:
20235421
18.

Modulation of the anti-cancer efficacy of microtubule-targeting agents by cellular growth conditions.

Dorsey JF, Dowling ML, Kim M, Voong R, Solin LJ, Kao GD.

Cancer Biol Ther. 2010 May 15;9(10):809-18.

19.

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells.

Dorsey JF, Mintz A, Tian X, Dowling ML, Plastaras JP, Dicker DT, Kao GD, El-Deiry WS.

Mol Cancer Ther. 2009 Dec;8(12):3285-95. doi: 10.1158/1535-7163.MCT-09-0415.

20.

The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer.

Crisanti MC, Wallace AF, Kapoor V, Vandermeers F, Dowling ML, Pereira LP, Coleman K, Campling BG, Fridlender ZG, Kao GD, Albelda SM.

Mol Cancer Ther. 2009 Aug;8(8):2221-31. doi: 10.1158/1535-7163.MCT-09-0138. Epub 2009 Aug 11.

21.

Mitotic checkpoint, aneuploidy and cancer.

Yen TJ, Kao GD.

Adv Exp Med Biol. 2005;570:477-99. doi: 10.1007/1-4020-3764-3_17. Review. No abstract available.

PMID:
18727512
22.

HDAC4 promotes growth of colon cancer cells via repression of p21.

Wilson AJ, Byun DS, Nasser S, Murray LB, Ayyanar K, Arango D, Figueroa M, Melnick A, Kao GD, Augenlicht LH, Mariadason JM.

Mol Biol Cell. 2008 Oct;19(10):4062-75. doi: 10.1091/mbc.E08-02-0139. Epub 2008 Jul 16.

23.

TRAIL inactivates the mitotic checkpoint and potentiates death induced by microtubule-targeting agents in human cancer cells.

Kim M, Liao J, Dowling ML, Voong KR, Parker SE, Wang S, El-Deiry WS, Kao GD.

Cancer Res. 2008 May 1;68(9):3440-9. doi: 10.1158/0008-5472.CAN-08-0014.

24.

Temozolomide-mediated radiosensitization of human glioma cells in a zebrafish embryonic system.

Geiger GA, Fu W, Kao GD.

Cancer Res. 2008 May 1;68(9):3396-404. doi: 10.1158/0008-5472.CAN-07-6396.

25.

Identification and biological evaluation of a novel and potent small molecule radiation sensitizer via an unbiased screen of a chemical library.

Lally BE, Geiger GA, Kridel S, Arcury-Quandt AE, Robbins ME, Kock ND, Wheeler K, Peddi P, Georgakilas A, Kao GD, Koumenis C.

Cancer Res. 2007 Sep 15;67(18):8791-9.

26.

"No Turning Bax" in the combined battle against prostate cancer:.

Rajendran RR, Kao GD.

Clin Cancer Res. 2007 Jun 15;13(12):3435-8. Review. No abstract available.

27.

Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation.

Kao GD, Jiang Z, Fernandes AM, Gupta AK, Maity A.

J Biol Chem. 2007 Jul 20;282(29):21206-12. Epub 2007 May 18.

28.

Tripin/hSgo2 recruits MCAK to the inner centromere to correct defective kinetochore attachments.

Huang H, Feng J, Famulski J, Rattner JB, Liu ST, Kao GD, Muschel R, Chan GK, Yen TJ.

J Cell Biol. 2007 May 7;177(3):413-24.

29.

Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells.

Cengel KA, Voong KR, Chandrasekaran S, Maggiorella L, Brunner TB, Stanbridge E, Kao GD, McKenna WG, Bernhard EJ.

Neoplasia. 2007 Apr;9(4):341-8.

30.

"Hood ornament" or "V-10 engine"? Myths and realities regarding physician-scientists in academic radiation oncology departments.

Kao GD, McKenna WG.

J Am Coll Radiol. 2004 Aug;1(8):539-44. No abstract available.

PMID:
17411649
31.

Aloe(-emodin) for cancer? More than just a comforting salve.

Dorsey JF, Kao GD.

Cancer Biol Ther. 2007 Jan;6(1):89-90. No abstract available.

PMID:
17297301
32.

A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity.

Li Y, Kao GD, Garcia BA, Shabanowitz J, Hunt DF, Qin J, Phelan C, Lazar MA.

Genes Dev. 2006 Sep 15;20(18):2566-79.

33.

Radiosensitizing effects of the prenyltransferase inhibitor AZD3409 against RAS mutated cell lines.

Cengel KA, Deutsch E, Stephens TC, Voong KR, Kao GD, Bernhard EJ.

Cancer Biol Ther. 2006 Sep;5(9):1206-10. Epub 2006 Sep 11.

PMID:
16969121
34.

Zebrafish as a "biosensor"? Effects of ionizing radiation and amifostine on embryonic viability and development.

Geiger GA, Parker SE, Beothy AP, Tucker JA, Mullins MC, Kao GD.

Cancer Res. 2006 Aug 15;66(16):8172-81.

36.
37.

Gamma radiation increases endonuclease-dependent L1 retrotransposition in a cultured cell assay.

Farkash EA, Kao GD, Horman SR, Prak ET.

Nucleic Acids Res. 2006 Feb 28;34(4):1196-204. Print 2006.

38.

Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: class differences and the potential influence of p53.

Kim IA, Shin JH, Kim IH, Kim JH, Kim JS, Wu HG, Chie EK, Ha SW, Park CI, Kao GD.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):940-9.

39.

Regulation of histone deacetylase 4 expression by the SP family of transcription factors.

Liu F, Pore N, Kim M, Voong KR, Dowling M, Maity A, Kao GD.

Mol Biol Cell. 2006 Feb;17(2):585-97. Epub 2005 Nov 9.

40.

Caspase-mediated specific cleavage of BubR1 is a determinant of mitotic progression.

Kim M, Murphy K, Liu F, Parker SE, Dowling ML, Baff W, Kao GD.

Mol Cell Biol. 2005 Nov;25(21):9232-48. Erratum in: Mol Cell Biol. 2007 Mar;27(5):1991.

41.

Protein kinase C delta stimulates apoptosis by initiating G1 phase cell cycle progression and S phase arrest.

Santiago-Walker AE, Fikaris AJ, Kao GD, Brown EJ, Kazanietz MG, Meinkoth JL.

J Biol Chem. 2005 Sep 16;280(37):32107-14. Epub 2005 Jul 28.

42.

Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents.

Dowling M, Voong KR, Kim M, Keutmann MK, Harris E, Kao GD.

Cancer Biol Ther. 2005 Feb;4(2):197-206. Epub 2005 Feb 8.

PMID:
15753652
43.
44.

Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells.

Lee EA, Keutmann MK, Dowling ML, Harris E, Chan G, Kao GD.

Mol Cancer Ther. 2004 Jun;3(6):661-9.

45.

Caspase-mediated specific cleavage of human histone deacetylase 4.

Liu F, Dowling M, Yang XJ, Kao GD.

J Biol Chem. 2004 Aug 13;279(33):34537-46. Epub 2004 Jun 17.

46.

Pictures, progress, and perplexities: the immediate cell biological effects of ionizing radiation.

Smith R, Kao GD.

Cancer Biol Ther. 2004 Jul;3(7):602-7. Epub 2004 Jul 21. Review.

PMID:
15153811
47.

Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response.

Kao GD, McKenna WG, Guenther MG, Muschel RJ, Lazar MA, Yen TJ.

J Cell Biol. 2003 Mar 31;160(7):1017-27.

48.

Assembly of the SMRT-histone deacetylase 3 repression complex requires the TCP-1 ring complex.

Guenther MG, Yu J, Kao GD, Yen TJ, Lazar MA.

Genes Dev. 2002 Dec 15;16(24):3130-5.

49.

Coupling of DNA synthesis and histone synthesis in S phase independent of cyclin/cdk2 activity.

Nelson DM, Ye X, Hall C, Santos H, Ma T, Kao GD, Yen TJ, Harper JW, Adams PD.

Mol Cell Biol. 2002 Nov;22(21):7459-72.

50.

Detection of repair activity during the DNA damage-induced G2 delay in human cancer cells.

Kao GD, McKenna WG, Yen TJ.

Oncogene. 2001 Jun 14;20(27):3486-96.

Supplemental Content

Support Center